Table 3 Association between characteristics of articles and statistically significant outcome or conclusions that favor the test drug: Multivariate logistic regression (full sample, n = 137)
| Â | Â | Results Favor Test Drug | Conclusions Favor Test Drug | ||||
|---|---|---|---|---|---|---|---|
Characteristic | Category | Favorable n/Total n (%) | OR (95% CI) | P | Favorable n/Total n (%) | OR (95% CI) | P |
Trial registration before publication | No | 44/83 (53) | 1.00 | Â | 55/83 (66) | 1.00 | Â |
| Â | Yes | 36/54 (67) | 1.29 (0.54-3.08) | 0.566 | 43/54 (80) | 1.56 (0.60-4.05) | 0.363 |
Blinding | Stringent | 18/36 (50) | 1.00 | Â | 25/36 (69) | 1.00 | Â |
| Â | Not stringent | 62/101 (61) | 2.33 (0.95-5.76) | 0.066 | 73/101 (72) | 1.51 (0.59-3.91) | 0.394 |
Sample Size | Natural log | - | 2.28 (1.49-3.48) | <0.001 | - | 1.77 (1.18-2.66) | 0.006 |
Comparison group | Active comparator | 35/65 (54) | 1.00 | Â | 45/65 (69) | 1.00 | Â |
| Â | Placebo | 45/72 (63) | 2.06 (0.87-4.90) | 0.101 | 53/72 (74) | 1.47 (0.59-3.63) | 0.410 |
Primary efficacy outcome | Survival | 17/30 (57) | 1.00 | Â | 21/30 (70) | 1.00 | Â |
| Â | Surrogate | 63/107 (59) | 3.42 (1.15-10.14) | 0.027 | 77/107 (72) | 3.04 (0.95-9.68) | 0.061 |
Sponsored | No | 14/28 (50) | 1.00 | Â | 15/28 (54) | 1.00 | Â |
| Â | Yes | 66/109 (61) | 1.01 (0.37-2.67) | 0.999 | 83/109 (76) | 2.01 (0.76-5.31) | 0.157 |